發(fā)布時間：2018-01-29 10:40

  本文關(guān)鍵詞： 糖尿病 脾虛 氧化應(yīng)激 炎癥　出處：《廣州中醫(yī)藥大學(xué)》2016年碩士論文　論文類型：學(xué)位論文

【摘要】：目的：此次試驗起源于于益氣健脾治療糖尿病的觀點(diǎn),結(jié)合氧化應(yīng)激和炎癥的研究熱點(diǎn),選擇糖尿病為研究病種,注重于體內(nèi)的炎癥狀態(tài)和血清氧化還原體系,主要分析2型糖尿病(Diabetes mellitus type 2, T2DM)患者炎癥和氧化應(yīng)激以及胰腺外分泌功能的變化,探討脾虛(Spleen deficiency)通過氧化應(yīng)激和炎癥方面對糖尿病的影響.方法：1、按照目前臨床通用的糖尿病診斷標(biāo)準(zhǔn)劃分糖尿病病例范圍,按照相關(guān)脾虛證的辨證標(biāo)準(zhǔn),在糖尿病患者內(nèi)選取30例患者設(shè)定為糖尿病脾虛組,選擇排除相關(guān)脾虛證癥狀的糖尿病患者30例作為糖尿病非脾虛組,健康體檢中心選擇20例作為正常組參考對照。2、收集上述人員血清,檢測其血清胰型淀粉酶(Pancreatic amylase, P-AMY);α淀粉酶(Alpha-amylase preparation, α-AMY);超敏C反應(yīng)蛋白(Highsensitivity C-reactive protein, hs-CRP);白細(xì)胞介素6(Interleukin 6, IL-6);腫瘤壞死因子α (Tumor necrosis factor-alpha, TNF-α);丙二醛(Malondialdhyde, MDA);蛋白質(zhì)羰基含量(Protein carbonyls content, PCO).3、指標(biāo)檢測時,采用酶聯(lián)免疫吸附測定法(ELISA)測定血清P-AMY, α-AMY含量；采用雙抗體夾心法(ELISA)測定血清炎癥因子hs-CRP、IL-6、TNF-α含量；采用硫代巴比妥酸(2-Thiobarbituric acid, TBA)法測定血清MDA水平;采用2,4二硝基苯肼(DNPH)比色法測定血清PCO含量.結(jié)果：糖尿病脾虛患者的P-AMY含量不明顯低于糖尿病非脾虛患者,高水平病例分布低于糖尿病非脾虛患者,正常組高水平病例分布多于糖尿病的兩組,但平均水平對比無統(tǒng)計學(xué)意義;糖尿病脾虛患者的α-AMY含量不明顯低于糖尿病非脾虛患者,高水平病例分布低于糖尿病非脾虛患者, 正常組高水平病例分布多于糖尿病的兩組,但平均水平對比無統(tǒng)計學(xué)意義；糖尿病脾虛患者的炎癥因子hs-CRP, TNF-α含量不明顯高于糖尿病非脾虛患者,高水平病例分布高于糖尿病非脾虛患者,正常組高水平病例分布低于糖尿病的兩組,但平均水平對比無統(tǒng)計學(xué)意義；糖尿病脾虛患者的炎癥因子IL-6含量明顯高于糖尿病非脾虛患者(P＜0.01),高水平病例分布高于糖尿病非脾虛患者,與正常組平均水平對比無統(tǒng)計學(xué)意義糖尿病脾虛患者的MDA, PCO含量高于糖尿病非脾虛患者,高水平病例分布高于糖尿病非脾虛患者,正常組高水平病例分布低于糖尿病的兩組,但平均水平對比無統(tǒng)計學(xué)意義；結(jié)論：脾虛有降低胰腺外分泌功能的趨勢,使血清胰型淀粉酶水平降低,脾虛有加重部分糖尿病患者體內(nèi)炎癥和氧化應(yīng)激的趨勢。
[Abstract]:Objective: this experiment originated from the point of view of invigorating qi and invigorating spleen to treat diabetes mellitus, combined with the research focus of oxidative stress and inflammation, select diabetes mellitus as the research disease, and focus on the inflammatory state and serum redox system in vivo. The changes of inflammation, oxidative stress and pancreatic exocrine function in patients with type 2 diabetes mellitus mellitus type 2 (T2DM) were analyzed. Objective: to investigate the effect of Spleen deficiency on diabetes mellitus by oxidative stress and inflammation. According to the current clinical general criteria for the diagnosis of diabetes mellitus cases divided into the scope, according to the relevant spleen deficiency syndrome differentiation criteria, 30 cases of diabetes patients were selected as the group of diabetes spleen deficiency. Thirty patients with diabetes without spleen deficiency syndrome were selected as non-spleen deficiency group, and 20 patients were selected as reference control group by the health examination center to collect the serum of the above mentioned persons. The serum levels of pancreatic amylase (Pancreatic amylase) and P-AMYYase were detected. 偽 -amylase preparation, 偽 -amylase, 偽 -amylase; High sensitivity C-reactive protein (hs-CRP); Interleukin 6, Interleukin 6, Interleukin 6; Tumor necrosis factor-alpha, TNF- 偽; Malondialdehyde (malondialdehyde); Protein carbonyls content, PCOC. 3, index detection. The contents of P-AMY, 偽 -AMY in serum were determined by enzyme-linked immunosorbent assay (Elisa). The level of serum inflammatory factor hs-CRPnIL-6 TNF- 偽 was determined by double antibody sandwich method (ELISAA). The serum MDA level was determined by thiobarbituric acid (TBA) method. The content of serum PCO was determined by DNPH colorimetry. Results: the content of P-AMY in diabetic patients with spleen deficiency was not significantly lower than that in patients with non-spleen deficiency of diabetes mellitus. The distribution of high level cases was lower than that of non-spleen deficiency diabetic patients, and the distribution of high level cases in normal group was higher than that in the two groups of diabetes mellitus, but the average level was not statistically significant. The content of 偽 -AMY in patients with spleen deficiency in diabetes mellitus was not significantly lower than that in patients with non-spleen deficiency of diabetes mellitus, the distribution of high level cases was lower than that in patients with non-spleen deficiency of diabetes mellitus, and the distribution of high level cases in normal group was more than that in two groups of diabetes mellitus. But the average level contrast has no statistical significance; The levels of inflammatory cytokines hs-CRP and TNF- 偽 in patients with spleen deficiency were not significantly higher than those in patients with non-spleen deficiency of diabetes mellitus, and the distribution of high level cases was higher than that in patients with non-spleen deficiency of diabetes mellitus. The distribution of high level cases in normal group was lower than that in diabetic group, but the average level was not statistically significant. The content of inflammatory factor IL-6 in diabetic patients with spleen deficiency was significantly higher than that in patients with non-spleen deficiency of diabetes (P < 0.01), and the distribution of high level cases was higher than that of patients with non-spleen deficiency of diabetes mellitus. Compared with the normal group, the average level of MDAand PCO in the patients with spleen deficiency was higher than that in the patients with non-spleen deficiency, and the distribution of the high level cases was higher than that in the patients with non-spleen deficiency of diabetes mellitus. The distribution of high level cases in normal group was lower than that in diabetic group, but the average level was not statistically significant. Conclusion: spleen deficiency has the tendency of decreasing pancreatic exocrine function, reducing serum pancreatic amylase level and exacerbating inflammation and oxidative stress in some diabetic patients with spleen deficiency.
【學(xué)位授予單位】：廣州中醫(yī)藥大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2016
【分類號】：R259

【參考文獻(xiàn)】

相關(guān)期刊論文 前7條

1 吳鈞俊;葉卓丁;;健脾益氣方對初診2型糖尿病患者胰島β細(xì)胞功能的影響[J];中醫(yī)學(xué)報;2015年04期

2 雷英;賀志有;劉麗莎;張帆;侯茜;;參苓白術(shù)散對脾虛證小鼠血清淀粉酶、D-木糖、胃泌素及小腸組織學(xué)變化的研究[J];中藥藥理與臨床;2012年02期

3 Shinji Kawahito;Hiroshi Kitahata;Shuzo Oshita;;Problems associated with glucose toxicity:Role of hyperglycemia-induced oxidative stress[J];World Journal of Gastroenterology;2009年33期

4 李宗芳;張澍;;脾臟的基礎(chǔ)研究進(jìn)展與展望[J];西安交通大學(xué)學(xué)報(醫(yī)學(xué)版);2008年01期

5 劉承琴,趙建群;2型糖尿病胰島素抵抗重視從脾論治的思路[J];新中醫(yī);2003年09期

6 林心舜，馮亞，，蔣向榮，林平;脾虛小鼠的吞噬細(xì)胞功能狀態(tài)及健脾合劑對其的影響[J];福建中醫(yī)學(xué)院學(xué)報;1995年01期

7 勞紹賢;脾虛證候的現(xiàn)代研究概況[J];新中醫(yī);1985年09期

本文編號：1473216